VKTX News and Press, Viking Therapeutics Inc. From 04/28/24

2024-04-28 09:07:00 ET Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller biotechs to see their stock prices skyrocket relatively quickly,...

2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...

2024-04-26 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you follow Warren Buffett’s advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis ce...

2024-04-24 19:58:10 ET Viking Therapeutics, Inc. (VKTX) Q1 2024 EarninConference Call April 24, 2024 08:30 A.M. ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Of...

2024-04-24 18:25:10 ET More on Viking Therapeutics Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeu...

2024-04-24 16:14:16 ET More on Viking Therapeutics Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeu...

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-...

2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...

Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...

2024-04-23 17:20:49 ET More on Viking Therapeutics Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeu...